Facebook
Twitter
Telegram
Report an ErrorIterum Therapeutics Balance Sheet 2011-2024 | ITRM
Annual Balance Sheet Iterum Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
5.75 M | -10.7 M | -20.1 M | 21.9 M | 8.62 M | -30.5 M | -8.48 M | -24.8 M | - | - | - | - | - |
Long Term Debt |
11.5 M | 10.1 M | 6.93 M | 35.9 M | 7.62 M | 13.1 M | - | - | - | - | - | - | - |
Long Term Debt Current |
365 K | 332 K | 464 K | 573 K | 580 K | 1.02 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 15 M | 14 M | 137 K | 30 K | - | - | - | - | - |
Total Current Liabilities |
13.5 M | 9.06 M | 12.9 M | 41.7 M | 37 M | 12.2 M | - | - | - | - | - | - | - |
Total Liabilities |
32.7 M | 38.8 M | 41.3 M | 83.4 M | 52 M | 26.2 M | 7.26 M | 4.25 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-461 M | -423 M | -378 M | -287 M | -235 M | -132 M | -54.7 M | -25.3 M | - | - | - | - | - |
Total Assets |
26.3 M | 66.8 M | 91.5 M | 32.8 M | 25.8 M | 97.9 M | 46.8 M | 26.9 M | - | - | - | - | - |
Cash and Cash Equivalents |
6.07 M | 21.1 M | 27.4 M | 14.5 M | 4.8 M | 44.6 M | - | - | - | - | - | - | - |
Book Value |
-6.4 M | 28 M | 50.2 M | -50.6 M | -26.2 M | 71.6 M | 39.5 M | 22.7 M | - | - | - | - | - |
Total Shareholders Equity |
-6.4 M | 28 M | 50.2 M | -50.6 M | -26.2 M | 71.6 M | 39.5 M | 22.7 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Iterum Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
11.2 M | 12.5 M | 11.7 M | 10.9 M | 10.1 M | 9.3 M | 8.5 M | 7.71 M | 6.93 M | 6.13 M | 5.34 M | 6.09 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
25.8 M | 36.3 M | 43.9 M | 39.2 M | 38.8 M | 39 M | 32.8 M | 35.4 M | 41.3 M | 46 M | 58.8 M | 83.6 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 52 M | 52 M | 52 M | 52 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 7.21 M | 7.21 M | 7.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-468 M | -449 M | -445 M | -433 M | -423 M | -418 M | -389 M | -382 M | -378 M | -374 M | -378 M | -386 M | -287 M | -287 M | -287 M | -287 M | -235 M | -235 M | -235 M | -235 M | -132 M | -132 M | -132 M | -132 M | -54.7 M | -54.7 M | -54.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
19.6 M | 39.7 M | 51 M | 58.1 M | 66.8 M | 71.6 M | 76.7 M | 84.1 M | 91.5 M | 98.4 M | 106 M | 115 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 97.9 M | 97.9 M | 97.9 M | 97.9 M | 46.8 M | 46.8 M | 46.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
7.39 M | 4.82 M | 13.7 M | 16.8 M | 21.1 M | 20.5 M | 9.21 M | 31.4 M | 27.4 M | 36 M | 36.6 M | 66.6 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 44.6 M | 44.6 M | 44.6 M | 44.6 M | 8.48 M | 8.48 M | 8.48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-6.15 M | 3.43 M | 7.13 M | 19 M | 28 M | 32.5 M | 43.9 M | 48.6 M | 50.2 M | 52.4 M | 47.2 M | 31.5 M | -50.6 M | -50.6 M | -50.6 M | -50.6 M | -26.2 M | -26.2 M | -26.2 M | -26.2 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 39.6 M | 39.6 M | 39.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-6.15 M | 3.43 M | 7.13 M | 19 M | 28 M | 32.5 M | 43.9 M | 48.6 M | 50.2 M | 52.4 M | 47.2 M | 31.5 M | 50.6 M | -50.6 M | -50.6 M | -50.6 M | -26.2 M | -26.2 M | -26.2 M | -26.2 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 39.5 M | 39.5 M | 39.5 M | - | 22.7 M | - | - | - | 15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency